文献速递骨肌MR

T2加权MRI影像组学在高恶性髓内骨肉瘤中的应用:预测化疗组织学反应、总生存期和无病生存期的准确性

T2-weighted MRI radiomics in high-grade intramedullary osteosarcoma: predictive accuracy in assessing histologic response to chemotherapy, overall survival, and disease-free survival.
PubMed 文献 · Skeletal Radiol · 2022-07-01

本研究评估105例经组织学证实的高恶性髓内骨肉瘤患者治疗前T2加权MRI的影像组学特征,预测新辅助化疗后肿瘤坏死、总生存期和无病生存期的准确性。预测组织学肿瘤坏死的模型平均AUC为0.708±0.046,预测总生存期和无病生存期的平均一致性指数分别为0.741±0.011和0.745±0.010。结论认为T2加权MRI影像组学模型作为潜在预后生物标志物显示出有希望的结果。

要点

  • 治疗前T2加权MRI影像组学模型预测化疗后组织学肿瘤坏死的平均AUC为0.708±0.046。
  • 预测总生存期的模型平均一致性指数为0.741±0.011,预测无病生存期的模型为0.745±0.010。
  • 最终模型分别采用11个特征预测组织学坏死、13个特征预测总生存期、12个特征预测无病生存期。

核心结论

  • T2加权MRI影像组学模型作为潜在预后生物标志物,在预测常规骨肉瘤对新辅助化疗的肿瘤反应和临床结局方面显示出有希望的结果。

研究设计与样本

  • 研究纳入105例连续接受新辅助化疗和切除术的高恶性髓内骨肉瘤患者,评估治疗前MRI检查;由两名阅片者进行分割提取影像组学特征,剔除可重复性差的特征;采用Cox比例风险模型和Spearman相关多变量建模分析影像组学特征与总生存期、无病生存期及组织学肿瘤坏死的关系。

诊断标准与关键数值

  • 预测组织学肿瘤坏死的最终影像组学模型采用11个特征,平均AUC为0.708±0.046。
  • 预测总生存期的模型采用13个影像组学特征,平均一致性指数为0.741±0.011。
  • 预测无病生存期的模型保留12个特征,平均一致性指数为0.745±0.010。
  • 组织学肿瘤坏死评估中,良好反应定义为坏死≥90%,104例中41例为良好反应,63例为不良反应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To analyze radiomic features obtained from pre-treatment T2-weighted MRI acquisitions in patients with histologically proven intramedullary high-grade osteosarcomas and assess the accuracy of radiomic modelling as predictive biomarker of tumor necrosis following neoadjuvant chemotherapy (NAC), overall survival (OS), and disease-free survival (DFS).

MATERIALS AND METHODS: Pre-treatment MRI exams in 105 consecutive patients who underwent NAC and resection of high-grade intramedullary osteosarcoma were evaluated. Histologic necrosis following NAC, and clinical outcome-survival data was collected for each case. Radiomic features were extracted from segmentations performed by two readers, with poorly reproducible features excluded from further analysis. Cox proportional hazard model and Spearman correlation with multivariable modelling were used for assessing relationships of radiomics features with OS, DFS, and histologic tumor necrosis.

RESULTS: Study included 74 males, 31 females (mean 32.5yrs, range 15-77 years). Histologic assessment of tumor necrosis following NAC was available in 104 cases, with good response (≥ 90% necrosis) in 41, and poor response in 63. Fifty-three of 105 patients were alive at follow-up (median 40 months, range: 2-213 months). Median OS was 89 months. Excluding 14 patients with metastases at presentation, median DFS was 19 months. Eleven radiomics features were employed in final radiomics model predicting histologic tumor necrosis (mean AUC 0.708 ± 0.046). Thirteen radiomic features were used in model predicting OS (mean concordance index 0.741 ± 0.011), and 12 features retained in predicting DFS (mean concordance index 0.745 ± 0.010).

CONCLUSIONS: T2-weighted MRI radiomic models demonstrate promising results as potential prognostic biomarkers of prospective tumor response to neoadjuvant chemotherapy and prediction of clinical outcomes in conventional osteosarcoma.

来源:Skeletal Radiol,查看原文。版权归原作者所有。

引用

  1. White, Atinga, Naraghi, et al. T2-weighted MRI radiomics in high-grade intramedullary osteosarcoma: predictive accuracy in assessing histologic response to chemotherapy, overall survival, and disease-free survival. Skeletal Radiol. 2022. PMID: 35778618. doi:10.1007/s00256-022-04098-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。